CervoMed to Participate in Upcoming Investor Conferences
August 27 2024 - 8:30AM
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on
developing treatments for age-related neurologic disorders, today
announced that the Company’s management will participate in the
following investor conferences during the month of September:
Morgan Stanley 22nd
Annual Global Healthcare ConferenceFormat:
Fireside ChatDate: Friday, September 6, 2024Time: 1:50 PM ETWebcast
Link: click here
H.C. Wainwright 26th Annual Global Investment
ConferenceFormat: Corporate PresentationDate: Wednesday,
September 11, 2024Time: 8:30 AM ETWebcast Link: click here
The webcast of these presentations will be accessible in the
Investor section of the CervoMed website
https://www.cervomed.com/.
About CervoMedCervoMed Inc. (the “Company”) is
a clinical-stage company focused on developing treatments for
age-related neurologic disorders. The Company is currently
developing neflamapimod, an investigational, orally administered
small molecule brain penetrant that inhibits p38 mitogen-activated
protein kinase alpha. Neflamapimod has the potential to treat
synaptic dysfunction, the reversible aspect of the underlying
neurodegenerative processes that causes disease in DLB and certain
other major neurological disorders. Neflamapimod is currently being
evaluated in a Phase 2b study in patients with early-stage DLB.
Investor Contact: PJ KelleherLifeSci
AdvisorsInvestors@cervomed.com617-430-7579
CervoMed (NASDAQ:CRVO)
Historical Stock Chart
From Jul 2024 to Aug 2024
CervoMed (NASDAQ:CRVO)
Historical Stock Chart
From Aug 2023 to Aug 2024